 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Thursday
Rasagiline Helpful as Adjunct Treatment in Parkinson's Disease: Presented at ANA
A subgroup analysis found that treatment with the second-generation monoamine oxidase type B inhibitor improves control of Parkinson's disease symptoms in patients being treated with levodopa, researchers reported here at the American Neurological Association (ANA) 131st Annual Meeting.
Data pooled from 2 clinical trials with rasagiline found that treatment with rasagiline reduces daily "off" time -- or the period when symptoms are evident -- and produces global improvements in patients with mild fluctuations at baseline, reported Steven Schwid, MD, associate professor of neurology, University of Rochester, New York, New York.
"Rasagiline produces significant efficacy benefits in patients with moderate Parkinson's disease," Dr. Schwid said in his poster presentation on October 10th.
In patients treated with levodopa monotherapy who were offered rasagiline as an adjunct treatment, "off" time was reduced by 1.44 hours a day with adjunct rasagiline in 133 patients, versus a reduction of 0.66 hours among the 120 patients who were not taking rasagiline. That difference reached statistical significance at the P < .01 level, Dr. Schwid reported....
A subgroup analysis found that treatment with the second-generation monoamine oxidase type B inhibitor improves control of Parkinson's disease symptoms in patients being treated with levodopa, researchers reported here at the American Neurological Association (ANA) 131st Annual Meeting.
Data pooled from 2 clinical trials with rasagiline found that treatment with rasagiline reduces daily "off" time -- or the period when symptoms are evident -- and produces global improvements in patients with mild fluctuations at baseline, reported Steven Schwid, MD, associate professor of neurology, University of Rochester, New York, New York.
"Rasagiline produces significant efficacy benefits in patients with moderate Parkinson's disease," Dr. Schwid said in his poster presentation on October 10th.
In patients treated with levodopa monotherapy who were offered rasagiline as an adjunct treatment, "off" time was reduced by 1.44 hours a day with adjunct rasagiline in 133 patients, versus a reduction of 0.66 hours among the 120 patients who were not taking rasagiline. That difference reached statistical significance at the P < .01 level, Dr. Schwid reported....